Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for active moderate to severe rheumatoid arthritis
ACTRN12608000397314Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 22
01
Overview
Phase 3, open-label trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Roche. Primary endpoints: Tolerability and Safety. Started Jul 2008; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ACTRN12608000397314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000397314.